iifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Glenmark Pharmaceuticals Secures License for Cancer Treatment Drug Envafolimab in Key Global Regions

25 Jan 2024 , 03:27 PM

Glenmark Pharmaceuticals Ltd's arm, Glenmark Specialty S A (GSSA), has signed a license agreement with Jiangsu Alphamab Biopharmaceuticals Co and 3D Medicines (Beijing) Co Ltd for KN035 (Envafolimab) used in cancer treatment.

The license agreement grants Glenmark rights for KN035 (Envafolimab) in India, Asia Pacific, the Middle East, Africa, Russia, CIS, and Latin America.

Glenmark will take on the responsibility for further development, registration, and commercialization of Envafolimab in these regions.

Jiangsu Alphamab, on behalf of the licensors, will receive a low double-digit million US dollar amount up to launch, additional triple-digit million US dollar milestone payments based on sales performance, and a royalty fee of single to double digits depending on net sales.

Jiangsu Alphamab will handle the manufacturing of KN035 and be the exclusive supplier of the product.

This deal is a significant milestone for Glenmark, providing access to the first recombinant humanized single domain antibody against PD-L1 in a Sub-Q formulation globally, according to Glenmark Pharmaceuticals Chairman & Managing Director Glenn Saldanha.

Envafolimab, approved as ENWEIDA in China in November 2021, is indicated for treating adult patients with certain types of advanced solid tumors. It is included in the 'List of Breakthrough Therapies' by the Chinese National Medical Products Administration.

Currently, Envafolimab is being developed in the USA by Tracon Pharma in a pivotal trial for soft tissue sarcoma (STS) subtypes.

The drug holds two orphan drug designations from the USFDA for advanced biliary tract cancer and STS, along with a fast-track designation for STS. Additional indications like biliary tract cancer and non-small cell lung cancer are in development.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Envafolimab
  • Glenmark Pharmaceuticals
  • news
sidebar mobile


15 Apr 2024   |   12:16 PM
15 Apr 2024   |   10:33 AM
15 Apr 2024   |   09:44 AM
Read More

Most Read News

15 Apr 2024   |   02:27 PM
15 Apr 2024   |   01:53 PM
15 Apr 2024   |   01:52 PM
Read More
Knowledge Centerplus

Logo IIFL Customer Care Number
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

Knowledge Centerplus

Follow us on


2024, IIFL Securities Ltd. All Rights Reserved

  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.


Get better recommendations & make better investments

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp